Another interesting observation was the 0.3-fold reduction in ARA levels in melanomas following in vivo JZL184 administration (Fig. 6F), whereas the levels of SAG and prostaglandins remained consistent between the two treatment groups (Fig. 6E,G,H). This evidence concerns the gene SAG and melanoma.